Pfizer's Vyndaqel and Vyndamax (tafamidis) treatments for TTR amyloidosis

0 Views
administrator
administrator
07/08/23

Dr. Adam Castano, Sr. Medical Director for ATTR Cardiac Amyloidosis at Pfizer, presents an update on Vyndaqel/Vyndamax (tafamidis), Pfizer's TTR stabilizer treatment, at ASG's 12/05/2020 ATTR webinar.

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next